21% org. growth, 52% EBIT growth, but stable sales into Q1 22% adj.
Order intake growth adds visibility Sports & outdoor demand should normalise during '24 '24e-'25e EB...
Ascelia’s priority is to secure a re-reader evaluation of SPARKLE by May 2024.
Redeye states that Catella had a quarter with weaker-than-expected performance from Investment Manag...
Redeye is now more optimistic on the near-term outlook following an array of orders from RemaSawco’s...
Redeye reviews Alligator Bioscience’s fourth quarter and the rights issue announced on Thursday even...
Redeye retains its positive view of Sdiptech following a Q4 report that was largely in-line with ou...
Redeye states that the report was below expectations.
Redeye takes a more positive view towards Hexatronic following a relative to expectations solid Q4 r...
Lower occupancy leads to negative est. revisions Acquisition potential remains, CEPS upside of ~20% ...
Fruitful restructuring - we revisit the Careium story Double-digit organic growth to persist in '24e...
Q4 hit by restructuring costs We lower estimates again Positive update on the cost savings for offic...
Redeye comments on Episurf Medical’s Q4 report and notes important key activities carried out in the...
Purefun är en svensk e-handelgrupp med flertalet varumärken och Norden som huvudmarknad.
Growth remains soft while we wait for new releases EBIT ests.
Förvaltningsresultat steg 32% under året och utdelningen höjs 36,5% till 4,64 kr per aktie.
Fortsatt press på den organiska tillväxten… Med en kombination av accelererande nedstängning av kopp...
Avslutar året med ett rekordkvartal Utvecklingen under det fjärde kvartalet var i linje med våra för...
Redeye sees only minor deviations in the Q4 numbers vs our expectations.
Redeye views the collaboration with AstraZeneca in lymphoma as another quality stamp for BI-1206.